Dulaglutide: Trulicity weekly diabetes & heart-protection drug

What this is

Dulaglutide (brand name Trulicity) is a once-weekly injectable medication approved by the FDA in September 2014 for glycemic control in type 2 diabetes and subsequently for cardiovascular risk reduction. It works by mimicking GLP-1, a gut hormone that stimulates insulin release after meals, suppresses glucagon, slows gastric emptying, and reduces appetite through brain satiety circuits. Structurally, dulaglutide is a fusion protein: two 30-amino-acid GLP-1 analog chains — each containing an Aib (2-aminoisobutyric acid) substitution at position 2 to resist enzymatic cleavage by DPP-4 — are covalently linked to a modified IgG4-Fc fragment via a peptide connector, giving the molecule a total weight of approximately 59.7 kDa. The stored 30-aa sequence (HXEGTFTSDVSSYLEGQAAKEFIAWLVKGR) represents one such GLP-1 pharmacophore chain; the "X" at position 2 encodes the non-proteinogenic Aib residue, and the full drug is a homodimer — two of these chains plus the IgG4-Fc heavy chain scaffold — which the raw sequence does not show.

History

Dulaglutide was developed by Eli Lilly as a second-generation GLP-1 receptor agonist designed to overcome the half-life limitations of native GLP-1 (cleaved by DPP-4 within minutes of release) and of first-generation analogs requiring daily injection. The Fc-fusion strategy had pharmaceutical precedent in biologics such as etanercept: linking a peptide to an IgG Fc fragment greatly extends half-life by exploiting neonatal Fc receptor (FcRn) recycling in endosomal compartments. Eli Lilly chose an IgG4 subclass Fc because IgG4 is the least pro-inflammatory IgG subtype — it does not activate complement or Fcγ receptors — while the Aib substitution at position 2 of the GLP-1 analog blocks DPP-4 cleavage at the His-Xaa scissile bond. Together these two modifications produce a plasma half-life of approximately 4.5–5 days in humans, enabling once-weekly subcutaneous dosing.

FDA approval arrived on September 18, 2014 for glycemic control in adults with type 2 diabetes, supported by the AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) Phase 3 program — eight pivotal trials covering monotherapy, add-on to metformin, insulin, sulfonylurea, and thiazolidinediones, with direct comparisons against exenatide twice-daily, sitagliptin, insulin glargine, and liraglutide once-daily. An additional label expansion for cardiovascular risk reduction in T2D patients with or at risk for atherosclerotic cardiovascular disease followed in September 2020, based on the results of the REWIND outcomes trial. Higher approved doses (3.0 mg and 4.5 mg weekly) were added in 2020 following AWARD-11 data. Dulaglutide's single-use auto-injector pen — with a hidden needle requiring no manual assembly — was a meaningful differentiator at launch compared with multi-step injection devices then in common use.

What it does

Dulaglutide activates GLP-1 receptors with a sustained pharmacodynamic profile across approximately one week from a single subcutaneous injection.

At the pancreas, GLP-1R activation on β-cells increases insulin secretion in a glucose-dependent manner through a Gαs → adenylyl cyclase → cAMP → PKA pathway that amplifies glucose-evoked insulin exocytosis. It simultaneously suppresses glucagon secretion from α-cells — directly and indirectly via δ-cell somatostatin — reducing hepatic glucose output postprandially. Critically, these effects are glucose-dependent: at normal or low blood glucose, neither insulin stimulation nor glucagon suppression is pronounced, explaining the low intrinsic hypoglycemia risk when dulaglutide is used without insulin or sulfonylureas.

In the central nervous system, GLP-1R expression in hypothalamic nuclei (arcuate, paraventricular, ventromedial), brainstem area postrema, and limbic structures mediates satiety signaling (increased POMC, reduced NPY/AgRP tone) and reduces the rewarding value of palatable foods. The resulting weight loss is modest compared with high-dose semaglutide or tirzepatide — averaging 2–3 kg in diabetes trials at the approved 1.5 mg dose.

In the stomach, GLP-1R activation slows gastric emptying, blunting postprandial glucose excursions and contributing to satiety, while also accounting for the most common adverse events (nausea, vomiting, diarrhea). Cardiovascular effects — including modest blood pressure reduction (~1–3 mmHg), a small improvement in lipid profile, and anti-atherosclerotic effects attributed to direct GLP-1R signaling in vascular endothelium — are proposed mechanisms underlying the REWIND cardiovascular outcome; whether the CV benefit is primarily metabolic or reflects direct vascular receptor effects remains an active research question.

Evidence

• Human: Extensive. The REWIND cardiovascular outcomes trial (Gerstein and colleagues, Lancet 2019; n=9,901; T2D patients with CV risk or established CVD; median 5.4-year follow-up) demonstrated a 12% relative reduction in 3P-MACE vs placebo (HR 0.88, 95% CI 0.79–0.99), with stroke as the most pronounced component (HR 0.76, 95% CI 0.61–0.95). Notably, 31.5% of enrolled patients had no established cardiovascular disease at baseline — the broadest-eligibility population of any GLP-1 RA cardiovascular outcomes trial at the time. REWIND also showed significant reduction in incident new macroalbuminuria and slowed eGFR decline in a pre-specified renal sub-analysis. The eight-trial AWARD Phase 3 program (Jendle and colleagues, Diabetes/Metabolism Research and Reviews 2016; pooled n>9,000) established consistent HbA1c reductions of 1.3–1.6 percentage points from baseline with the 1.5 mg dose across diverse backgrounds and comparators: dulaglutide was non-inferior to liraglutide 1.8 mg daily (AWARD-6) and superior to exenatide twice-daily (AWARD-1) and sitagliptin (AWARD-5). Body weight reductions across AWARD trials ranged from –0.5 to –2.9 kg with 1.5 mg; GI adverse events (nausea, diarrhea, vomiting) were predominantly mild-to-moderate and transient, peaking in the first 4–8 weeks. FDA-approved since 2014.
• Animal: Comprehensive preclinical characterization; GLP-1R mechanism well-established across rodent and non-human primate models. Rodent studies showed C-cell hyperplasia and medullary thyroid carcinoma at supratherapeutic doses, giving rise to the class-wide boxed warning.
• In vitro: GLP-1R agonism well-characterized; DPP-4 resistance of the Aib-2 modification confirmed in enzymatic studies; IgG4-Fc interaction with FcRn recapitulated in binding assays.

Myths and misconceptions

• "Dulaglutide is just a generic form of semaglutide" — Dulaglutide (Trulicity, Eli Lilly) and semaglutide (Ozempic/Wegovy, Novo Nordisk) are structurally distinct molecules from different manufacturers using different half-life extension strategies: dulaglutide uses Fc-fusion; semaglutide uses fatty acid conjugation to albumin. In the SUSTAIN-7 head-to-head trial, semaglutide achieved larger HbA1c reductions and approximately three times greater weight loss than dulaglutide at comparable doses. They are not interchangeable.
• "All GLP-1 receptor agonists have proven cardiovascular benefit" — Cardiovascular outcomes have been formally demonstrated for liraglutide (LEADER trial), subcutaneous semaglutide (SUSTAIN-6), dulaglutide (REWIND), and efpeglenatide (AMPLITUDE-O). Exenatide (EXSCEL) and lixisenatide (ELIXA) showed CV neutrality. CV benefit is not a class-wide certainty and has varied among agents in their respective trials.
• "Dulaglutide can be used without a diabetes diagnosis for weight loss" — The approved indication is specifically type 2 diabetes glycemic control and CV risk reduction. At approved doses, dulaglutide produces only modest weight loss (approximately 2–3 kg), insufficient for a weight management indication. Semaglutide (Wegovy) and tirzepatide (Zepbound) have explicit weight management approvals for patients without T2D; dulaglutide does not.
• "The Fc fusion makes dulaglutide immunogenic or inflammatory" — IgG4 was specifically chosen because it does not fix complement, has minimal Fcγ receptor binding, and is the least immunostimulatory IgG subclass. Anti-dulaglutide antibodies developed in a small percentage of trial participants but did not attenuate efficacy or cause immune-mediated adverse events.
• "Nausea with dulaglutide is permanent" — GI side effects are most pronounced in the first 4–8 weeks and diminish with continued dosing as GLP-1R-mediated gastric slowing is partially accommodated.

Common questions

How does once-weekly dosing compare to daily injectables for real-world adherence? Retrospective claims analyses and head-to-head adherence studies consistently show that once-weekly regimens have higher adherence and persistence than once-daily injectables in type 2 diabetes. The Trulicity auto-injector device — with a hidden needle requiring no manual assembly — additionally reduces injection anxiety. These practical features contributed to dulaglutide's rapid market uptake after launch.

Does dulaglutide protect the kidneys? A pre-specified secondary analysis of REWIND (Gerstein and colleagues, Lancet 2019) showed dulaglutide significantly reduced incident macroalbuminuria and sustained ≥30% eGFR decline versus placebo. The AWARD-7 trial specifically enrolled T2D patients with moderate-to-severe chronic kidney disease and reported renal-protective signals, including a 39% reduction in urine albumin-to-creatinine ratio with the 1.5 mg dose. The mechanism likely involves both metabolic improvement (reduced glomerular hyperfiltration) and direct GLP-1R effects on renal tubular cells.

Does dulaglutide increase the risk of thyroid cancer? GLP-1 receptors are expressed on thyroid C-cells (parafollicular cells that secrete calcitonin). In rodents, GLP-1 RA administration causes dose-dependent C-cell hyperplasia and medullary thyroid carcinoma. This finding has not been replicated in human clinical trials or epidemiological studies, but all GLP-1 RAs carry a boxed warning against use in patients with a personal or family history of medullary thyroid carcinoma or MEN-2.

How does dulaglutide compare to tirzepatide? Tirzepatide is a dual GLP-1R/GIPR agonist developed by Eli Lilly from the same company. In the SURPASS-2 head-to-head trial (n=1,879, T2D), tirzepatide at all tested doses was superior to dulaglutide 1.5 mg for both HbA1c reduction (–2.01 to –2.30% vs –1.34%) and weight loss (–7.8 to –11.3 kg vs –2.8 kg). Tirzepatide has largely superseded dulaglutide where maximum glycemic and weight efficacy is the clinical priority; dulaglutide retains relevance in step-therapy protocols, cost-constrained settings, and for patients where the REWIND cardiovascular outcomes data is specifically relevant.

Known effects

• Glycemic control (HbA1c reduction) — FDA-approved; HbA1c reductions of 1.3–1.6 percentage points at 1.5 mg across AWARD Phase 3 trials (Jendle and colleagues 2016)
• Cardiovascular risk reduction (MACE) — FDA-approved (label expansion 2020); 12% relative reduction in 3P-MACE in REWIND (Gerstein and colleagues 2019)
• Modest weight loss — Phase III; 2–3 kg at 1.5 mg across AWARD trials; not an approved weight management indication
• Renal protection (albuminuria reduction) — Phase III sub-analysis; significant reduction in macroalbuminuria in REWIND renal analysis and AWARD-7
• Blood pressure reduction — Phase III; small, consistent effect (~1–3 mmHg) observed across trials

Safety signals

Nausea, diarrhea, vomiting, and abdominal pain are the most common adverse events and are predominantly mild-to-moderate in severity, occurring most frequently in the first 4–8 weeks of treatment; AWARD program data show declining incidence with continued use (Jendle and colleagues 2016). Hypoglycemia risk is low as monotherapy given the glucose-dependent mechanism, but increases meaningfully when combined with insulin or sulfonylureas.

A class-wide boxed warning applies to all GLP-1 RAs: thyroid C-cell tumors were observed in rodents at supratherapeutic doses; human relevance is unestablished but the signal prompted the warning. Pancreatitis cases have been reported across the GLP-1 RA class; REWIND showed balanced pancreatitis rates between dulaglutide and placebo arms (Gerstein and colleagues 2019). Gallbladder disease (cholelithiasis, cholecystitis) has been observed across GLP-1 RA trials, consistent with weight loss-related effects on bile composition. Anti-dulaglutide antibodies developed in a small proportion of AWARD trial participants without clinical consequence. The IgG4-Fc scaffold was chosen specifically to minimize immunostimulatory effects, and no immune-mediated adverse events attributable to the Fc component have been reported in trial data.

Regulatory status

• US: Prescription-only. FDA-approved (September 2014) for glycemic control in adults with type 2 diabetes; label expanded in 2020 to include reduction of major adverse cardiovascular events in T2D adults with established CV disease or multiple CV risk factors. Higher doses (3.0 mg and 4.5 mg) approved in 2020 based on AWARD-11 data. Not approved for chronic weight management.
• EU/UK: EMA-authorized (Trulicity 2014); MHRA-authorized (UK). Approved for T2D on parallel indications.
• Canada/Australia: Health Canada and TGA authorized for T2D indications.
• WADA: Not listed by name on the current WADA Prohibited List.

Related peptides

• Semaglutide — fatty acid–conjugated GLP-1 RA; superior HbA1c and weight reduction vs dulaglutide at approved doses; approved for T2D and obesity
• Liraglutide — once-daily GLP-1 RA; non-inferior to dulaglutide weekly in AWARD-6; first in class for cardiovascular outcomes (LEADER trial)
• Exenatide — first-in-class GLP-1 RA; twice-daily; inferior to dulaglutide in AWARD-1
• Tirzepatide — dual GLP-1R/GIPR agonist (Eli Lilly); superior to dulaglutide on glycemic and weight outcomes in SURPASS-2